Ribo and Boehringer Advance siRNA MASH Program
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
IRVINE, Calif., May 6, 2026 Helio Genomics announced publication of landmark clinical data demonstrating that its HelioLiverâ„¢ multi-analyte blood...
